Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Debra Josephs

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
European Urology|February 5, 2019
Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi MethodAgustina Bessa, Steven Maclennan, Deborah Enting, et al.
BJU International|January 20, 2011
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysisDebra Josephs, Thomas E Hutson, Charles L Cowey, et al.
BMC Cancer|September 26, 2020
Cohort profile: King's Health Partners bladder cancer biobankPinky Kotecha, Charlotte L Moss, Deborah Enting, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2014
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancerSarah Blagden, Aurelius Omlin, Aurelius Olmin, et al.
Frontiers in Oncology|January 24, 2024
A cohort profile of the Graham Roberts study cohortBeth Russell, Poppy Leech, Harriet Wylie, et al.
Clinical Lung Cancer|February 6, 2025
A Retrospective Evaluation of PD-L1 Expression and Heterogeneity in Early-Stage Non-Small Cell Lung Cancer (REPLICA)Eleni C Josephides, Daniel Smith, Andrea Bille, et al.
Cancers|December 23, 2022
Non-Small Cell Lung Cancer (NSCLC) in Young Adults, Age < 50, Is Associated with Late Stage at Presentation and a Very Poor Prognosis in Patients That Do Not Have a Targeted Therapy Option: A Real-World StudyDaniel Johnathan Hughes, Matthaios Kapiris, Andreja Podvez Nevajda, et al.
British Journal of Cancer|April 5, 2025
PD-L1 imaging with [<sup>99m</sup>Tc]NM-01 SPECT/CT is associated with metabolic response to pembrolizumab with/without chemotherapy in advanced lung cancerDaniel Johnathan Hughes, Gitasha Chand, Jessica Johnson, et al.
British Journal of Cancer|July 15, 2022
Radical cancer treatment is safe during COVID-19: the real-world experience of a large London-based Comprehensive Cancer Centre during the first waveBeth Russell, Charlotte Moss, Maria Monroy-Iglesias, et al.
Cancers|June 2, 2021
COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer PatientsBeth Russell, Charlotte L Moss, Kieran Palmer, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
European Urology|February 5, 2019
Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi MethodAgustina Bessa, Steven Maclennan, Deborah Enting, et al.
BJU International|January 20, 2011
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysisDebra Josephs, Thomas E Hutson, Charles L Cowey, et al.
BMC Cancer|September 26, 2020
Cohort profile: King's Health Partners bladder cancer biobankPinky Kotecha, Charlotte L Moss, Deborah Enting, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2014
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancerSarah Blagden, Aurelius Omlin, Aurelius Olmin, et al.
Frontiers in Oncology|January 24, 2024
A cohort profile of the Graham Roberts study cohortBeth Russell, Poppy Leech, Harriet Wylie, et al.
Clinical Lung Cancer|February 6, 2025
A Retrospective Evaluation of PD-L1 Expression and Heterogeneity in Early-Stage Non-Small Cell Lung Cancer (REPLICA)Eleni C Josephides, Daniel Smith, Andrea Bille, et al.
Cancers|December 23, 2022
Non-Small Cell Lung Cancer (NSCLC) in Young Adults, Age < 50, Is Associated with Late Stage at Presentation and a Very Poor Prognosis in Patients That Do Not Have a Targeted Therapy Option: A Real-World StudyDaniel Johnathan Hughes, Matthaios Kapiris, Andreja Podvez Nevajda, et al.
British Journal of Cancer|April 5, 2025
PD-L1 imaging with [<sup>99m</sup>Tc]NM-01 SPECT/CT is associated with metabolic response to pembrolizumab with/without chemotherapy in advanced lung cancerDaniel Johnathan Hughes, Gitasha Chand, Jessica Johnson, et al.
British Journal of Cancer|July 15, 2022
Radical cancer treatment is safe during COVID-19: the real-world experience of a large London-based Comprehensive Cancer Centre during the first waveBeth Russell, Charlotte Moss, Maria Monroy-Iglesias, et al.
Cancers|June 2, 2021
COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer PatientsBeth Russell, Charlotte L Moss, Kieran Palmer, et al.
Pageof 3